Atea Pharmaceuticals Inc
AVIR3.270USD
+0.020+0.62%
收盘 11/07, 16:00（美东）报价延迟15分钟
265.32M总市值
亏损市盈率 TTM
关于 Atea Pharmaceuticals Inc 公司
Atea Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。该公司正在进行一项 3 期临床试验，评估 bemnifosbuvir 治疗 2019 冠状病毒病 (COVID-19) 的效果。该公司还正在进行一项 2 期临床试验，评估 bemnifosbuvir 和 ruzasvir 联合治疗丙型肝炎病毒 (HCV) 的效果。bemnifosbuvir (AT-527) 是一种研究性、新型、口服鸟苷核苷酸类似物聚合酶抑制剂，它将独特的核苷酸支架与新型双前体药物相结合，旨在抑制病毒复制的核心酶。SUNRISE-3 旨在评估 bemnifosbuvir 作为单一疗法的效果，但它也在探索联合疗法对较小部分患者的影响。
Atea Pharmaceuticals Inc简介
公司代码AVIR
公司名称Atea Pharmaceuticals Inc
上市日期Oct 30, 2020
CEODr. Jean-Pierre Sommadossi, Ph.D.
员工数量56
证券类型Ordinary Share
年结日Oct 30
公司地址225 Franklin Street
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02110
电话18572048109
网址https://ateapharma.com/
公司代码AVIR
上市日期Oct 30, 2020
CEODr. Jean-Pierre Sommadossi, Ph.D.
Atea Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
Dr. Maria Arantxa Horga, M.D.
Dr. Maria Arantxa Horga, M.D.
Chief Medical Officer
Chief Medical Officer
60.88K
--
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
45.71K
+28.00%
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Janet Hammond, M.D., Ph.D.
Dr. Janet Hammond, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
收入明细
FY2022
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
BML Capital Management LLC
9.59%
BlackRock Institutional Trust Company, N.A.
8.04%
JPM Partner LLC
7.39%
Fidelity Management & Research Company LLC
7.21%
Tang Capital Management, LLC
6.16%
其他
61.61%
持股股东
持股股东
占比
BML Capital Management LLC
9.59%
BlackRock Institutional Trust Company, N.A.
8.04%
JPM Partner LLC
7.39%
Fidelity Management & Research Company LLC
7.21%
Tang Capital Management, LLC
6.16%
其他
61.61%
股东类型
持股股东
占比
Investment Advisor
41.88%
Investment Advisor/Hedge Fund
13.57%
Hedge Fund
10.58%
Corporation
7.39%
Individual Investor
5.32%
Family Office
4.26%
Research Firm
1.09%
Pension Fund
0.35%
Bank and Trust
0.17%
其他
15.39%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
237
53.79M
67.78%
-6.81M
2025Q2
265
64.93M
76.05%
-9.01M
2025Q1
301
65.12M
76.13%
-9.02M
2024Q4
315
66.52M
78.76%
-10.39M
2024Q3
317
68.18M
80.76%
-8.54M
2024Q2
318
67.11M
79.66%
-7.40M
2024Q1
325
64.40M
76.50%
-9.70M
2023Q4
340
64.58M
77.29%
-9.97M
2023Q3
373
64.87M
77.77%
-27.38M
2023Q2
383
65.08M
78.05%
-32.20M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BML Capital Management LLC
7.61M
9.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.38M
8.04%
-272.13K
-4.09%
Jun 30, 2025
JPM Partner LLC
5.87M
7.39%
--
--
Apr 22, 2025
Fidelity Management & Research Company LLC
5.72M
7.21%
-298.26K
-4.96%
Jun 30, 2025
Tang Capital Management, LLC
4.89M
6.16%
+89.20K
+1.86%
Jun 30, 2025
The Vanguard Group, Inc.
4.89M
6.16%
+159.52K
+3.37%
Jun 30, 2025
Radoff Family Foundation
3.38M
4.26%
+275.00K
+8.86%
Apr 16, 2025
Bain Capital Life Sciences Investors, LLC
2.49M
3.13%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.43%
-51.76K
-2.62%
Jun 30, 2025
State Street Investment Management (US)
1.78M
2.24%
+5.71K
+0.32%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ALPS Medical Breakthroughs ETF
0.13%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
占比0.13%
iShares Micro-Cap ETF
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
